888-969-2592
Kalkine 0
countryflagCA

Sarepta Therapeutics Inc

Healthcare US SRPT

19.16USD
-0.21(1.08%)

Last update at 2025-07-10T18:52:00Z

Day Range

18.5019.53
LowHigh

52 Week Range

55.25146.68
LowHigh

Fundamentals

  • Previous Close 19.37
  • Market Cap10609.35M
  • Volume1991777
  • P/E Ratio261.02
  • Dividend Yield-%
  • EBITDA-52.99500M
  • Revenue TTM1403.30M
  • Revenue Per Share TTM14.95
  • Gross Profit TTM -78.06600M
  • Diluted EPS TTM0.43

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -689.96300M -418.94800M -553.06500M -713.88000M -362.61000M
Minority interest - - - - -
Net income -703.48800M -418.78000M -554.12800M -715.07500M -361.91800M
Selling general administrative 451.42M 282.66M 317.88M 284.81M 209.98M
Selling and marketing expenses - - - - 2.22M
Gross profit 793.02M 604.84M 476.72M 324.25M 266.84M
Reconciled depreciation 41.86M 38.02M 26.91M 30.55M 12.24M
Ebit -536.20100M -449.71000M -564.16300M -522.32300M -343.62800M
Ebitda -473.53500M -412.11800M -529.27600M -469.42400M -342.76300M
Depreciation and amortization 62.67M 37.59M 34.89M 52.90M 0.86M
Non operating income net other - 40.76M 11.10M -8.31700M -18.98200M
Operating income -536.20100M -449.71000M -564.16300M -522.32300M -343.62800M
Other operating expenses 1469.21M 1151.60M 1104.26M 903.16M 644.66M
Interest expense 53.25M 63.52M 59.95M 30.67M 33.71M
Tax provision 13.53M -0.16800M 1.06M 1.20M -0.69200M
Interest income 16.49M 0.35M 2.97M 7.24M 6.81M
Net interest income -36.76000M -63.17100M -56.97700M -23.43100M -26.89900M
Extraordinary items - - - - -
Non recurring - - - 173.24M -
Other items - - - - -
Income tax expense 13.53M -0.16800M 1.06M 1.20M -0.69200M
Total revenue 933.01M 701.89M 540.10M 380.83M 301.03M
Total operating expenses 1329.22M 1054.55M 1040.88M 846.57M 610.47M
Cost of revenue 139.99M 97.05M 63.38M 56.59M 34.19M
Total other income expense net -153.76200M 30.76M 11.10M -191.55700M 10.14M
Discontinued operations - - - - -
Net income from continuing ops -703.48800M -418.78000M -554.12800M -715.07500M -361.91800M
Net income applicable to common shares -703.48800M -418.78000M -554.12800M -715.07500M -361.91800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 3264.58M 3128.37M 3147.97M 2984.72M 1822.82M
Intangible assets 29.62M 7.58M 14.24M 13.63M 12.50M
Earning assets - - - - -
Other current assets 140.52M 7.72M 6.14M 4.07M 5.25M
Total liab 2405.24M 2743.42M 2219.97M 2222.96M 1004.63M
Total stockholder equity 859.34M 384.95M 928.01M 761.76M 818.19M
Deferred long term liab - - - - -
Other current liab 315.00M 419.00M 15.05M 22.14M 196.67M
Common stock 0.00900M 0.00900M 0.00900M 0.00800M 0.00800M
Capital stock 0.00900M 0.00900M 0.00900M 0.00800M 0.00800M
Retained earnings -4446.21300M -3910.23600M -3206.74800M -2848.12900M -2294.00100M
Other liab - 521.94M 628.84M 734.07M 10.25M
Good will - - - - -
Other assets 0.00000M 286.62M 292.95M 295.46M 141.92M
Cash 428.43M 966.78M 2115.87M 1502.65M 835.08M
Cash and equivalents - - - - -
Total current liabilities 653.66M 619.60M 452.73M 416.03M 264.77M
Current deferred revenue 50.42M 89.24M 89.24M 89.24M -
Net debt 968.38M 650.58M -977.48100M -429.78800M -105.46000M
Short term debt 123.33M 15.49M 271.70M 193.55M -
Short long term debt 105.48M - - - -
Short long term debt total 1396.81M 1617.36M 1138.39M 1072.86M 729.62M
Other stockholder equity 5304.62M 4296.84M 4134.77M 3609.88M 3112.13M
Property plant equipment - 244.99M 191.16M 190.43M 129.62M
Total current assets 2579.33M 2557.86M 2604.10M 2485.20M 1468.91M
Long term investments 6.53M 31.32M 34.89M 38.80M 31.94M
Net tangible assets - 377.37M 913.77M 748.13M 805.69M
Short term investments 1247.82M 1022.60M 0.00000M 435.92M 289.67M
Net receivables 439.71M 259.70M 171.64M 138.58M 93.94M
Long term debt 1132.52M 1544.29M 1096.88M 992.49M 681.90M
Inventory 322.86M 203.97M 186.21M 231.96M 171.38M
Accounts payable 164.92M 95.88M 76.74M 111.09M 68.09M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.92M -1.66400M -0.02000M 0.00300M 0.05M
Additional paid in capital - - - - -
Common stock total equity - - 0.00900M 0.00800M 0.00800M
Preferred stock total equity - - - - -
Retained earnings total equity - - -3206.74800M -2848.12900M -2294.00100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 276.41M 286.62M 143.28M 12.98M 11.80M
Deferred long term asset charges - - - - -
Non current assets total 685.24M 570.50M 543.88M 499.52M 353.91M
Capital lease obligations 158.81M 57.58M 41.51M 80.37M 47.72M
Long term debt total - - 1096.88M 992.49M 681.90M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1046.88300M 436.01M -144.08800M 521.99M -305.79000M
Change to liabilities 58.33M -89.24400M 749.43M 122.98M 90.16M
Total cashflows from investing activities -1046.88300M 495.41M -121.72100M 286.73M -370.48800M
Net borrowings 304.17M 304.17M 291.11M 244.94M -3.48100M
Total cash from financing activities 232.51M 561.57M 682.32M 642.55M 530.15M
Change to operating activities 14.62M 103.20M -166.32800M -102.09100M -136.63800M
Net income -703.48800M -418.78000M -554.12800M -715.07500M -361.91800M
Change in cash -1139.72200M 613.81M 668.07M 472.82M -228.99800M
Begin period cash flow 2125.52M 1511.71M 843.64M 370.83M 599.83M
End period cash flow 985.80M 2125.52M 1511.71M 843.64M 370.83M
Total cash from operating activities -325.34600M -443.17200M 107.47M -456.46300M -388.66000M
Issuance of capital stock 0.00000M 548.53M 312.05M 365.35M 513.41M
Depreciation 41.86M 38.02M 26.91M 30.55M 12.24M
Other cashflows from investing activities -2.42700M 97.89M 104.57M -175.63800M -3.54100M
Dividends paid - - - - -
Change to inventory -50.78000M -83.77200M -60.58200M -45.93400M -41.84000M
Change to account receivables -61.63800M -51.65000M -10.46100M -41.83500M -19.57600M
Sale purchase of stock - 20.80M 396.01M 401.95M 563.63M
Other cashflows from financing activities 1025.70M 13.04M 370.27M 277.20M 283.96M
Change to netincome 375.75M 31.63M 178.05M 273.98M 76.58M
Capital expenditures 30.82M 38.49M 82.20M 62.71M 64.34M
Change receivables - -51.65000M -10.46100M -41.83500M -19.57600M
Cash flows other operating - 130.62M -221.75700M 41.86M -54.14800M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 613.81M 668.07M 472.82M -228.99800M
Change in working capital -39.47000M -98.16600M 554.06M -66.88100M -107.89200M
Stock based compensation 233.02M 113.94M 108.07M 78.60M 50.13M
Other non cash items 142.73M -93.99900M -38.08500M 224.79M 20.19M
Free cash flow -356.17000M -481.66200M 25.26M -519.17600M -453.00500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SRPT
Sarepta Therapeutics Inc		 -0.21 1.08% 19.16 261.02 35.21 9.28 13.43 9.06 -24.8209
NVO
Novo Nordisk A/S		 1.76 2.53% 71.45 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.68 2.41% 71.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.59 0.33% 480.56 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.98 1.08% 558.56 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics Inc

215 First Street, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Mr. Douglas S. Ingram Esq. Pres, CEO & Director 1963
Mr. Ian Michael Estepan Exec. VP & CFO 1976
Mr. William F. Ciambrone Exec. VP of Technical Operations 1964
Dr. Louise R. Rodino-Klapac Ph.D. Exec. VP, Chief Scientific Officer and Head of R&D 1978
Mr. Ryan E. Brown Sr. VP, Gen. Counsel & Corp. Sec. 1978
Bilal Arif Sr. VP of Strategy and Operations NA
Mary Jenkins Sr. Mang. of Investor Relations NA
Ms. Alison Nasisi Chief People Officer & VP NA
Dr. Diane L. Berry Sr. VP of Global Health Policy and Gov. & Patient Affairs NA
Mr. Dallan Murray Sr. VP & Chief Customer Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.